GlassScriptPhysician profile
Stephen D Beck
NPI 1326034745
$1,472.72
in general payments reported to CMS, 2019-2025
24 companies · $444 in 2025
The $444 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $54.09 · 2020: $83.87 · 2021: $304 · 2022: $286 · 2023: $77.37 · 2024: $224 · 2025: $444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $745.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $745.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cumberland Pharmaceuticals, INC. | $293.58 | 2021-2024 | Caldolor |
| Bioprotect Medical, INC. | $164.91 | 2025 | Bioprotect Balloon Implant System |
| Takeda Pharmaceuticals U.S.A., INC. | $153.12 | 2021 | |
| Boston Scientific Corporation | $150.38 | 2020-2025 | Axonics, General - Bph |
| Medtronic, INC. | $144.94 | 2021-2025 | Interstim |
| Axonics, INC. | $90.74 | 2020-2024 | Axonics, Bulkamid |
| Teleflex LLC | $66.15 | 2021-2025 | Barrigel, Urolift |
| Neotract INC. | $53.59 | 2019-2020 | |
| Urogen Pharma, INC. | $51.31 | 2025 | |
| Procept Biorobotics Corporation | $48.60 | 2022-2025 | Aquabeam System |
| Endo Pharmaceuticals INC. | $42.68 | 2019-2022 | |
| 180 Medical, INC. | $28.84 | 2024 | |
| Allergan, INC. | $23.01 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $19.93 | 2025 | |
| Biofrontera INC. | $19.92 | 2023 | Ameluz, Xepi, Bf-Rhodoled |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $18.27 | 2024 | Adstiladrin |
| Amgen INC. | $16.40 | 2024 | |
| Ucb, INC. | $15.74 | 2024 | Bimzelx |
| Tolmar, INC. | $15.52 | 2024 | |
| Pacira Pharmaceuticals Incorporated | $14.68 | 2021 | |
| Medline Industries LP | $13.93 | 2023 | |
| Heron Therapeutics, INC. | $12.96 | 2022 | |
| Medtronic USA, INC. | $12.38 | 2019 | |
| Laborie Medical Technologies Corp. | $1.14 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.